Tysabri (natalizumab) — the complete 2026 guide: how it works, AFFIRM efficacy, PML risk, and access in Serbia
Tysabri (natalizumab) is one of the most effective therapies for highly active relapsing-remitting MS — a monoclonal antibody that blocks lymphocyte entry into the brain. A detailed guide: mechanism, AFFIRM/SENTINEL data, PML risk stratification, the subcutaneous injection, pregnancy, rebound on discontinuation, and status on RFZO Lista C.
What is Tysabri
In conversations with people in the MS community, this is one of the questions that keeps coming back. Tysabri is the brand name for natalizumab, a humanised monoclonal antibody that binds α4-integrin (VLA-4) on lymphocytes and prevents them from crossing the blood-brain barrier. Developed by Biogen and Elan, approved by the FDA and EMA in 2004 ([Biogen press 2004](https://investors.biogen.com/news-releases/news-release-details/biogen-idec-and-elan-receive-fda-approval-tysabri); [EMA EPAR — Tysabri](https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri)). It was the first selective adhesion-molecule inhibitor and reset the bar for high-efficacy MS therapy — with the largest single-trial reduction in relapse rate seen at that time.
How it works
To cause damage in the brain, lymphocytes must first cross the blood-brain barrier — they do so by binding α4β1 integrin (VLA-4) to VCAM-1 on brain endothelium. Natalizumab blocks that interaction, so autoreactive T and B cells physically cannot enter the CNS. The result is near-complete shutdown of new MRI lesion formation within the first few infusions ([Polman CH et al. NEJM 2006 — AFFIRM](https://www.nejm.org/doi/full/10.1056/NEJMoa044397)).
The same mechanism explains the main risk — PML: when CNS surveillance of the JC virus is impaired because T cells cannot enter, latent JCV can reactivate and cause progressive multifocal leukoencephalopathy.
Who it is approved for
- Highly active relapsing-remitting MS (RRMS) in adults — patients with ≥1 relapse in the prior year and MRI activity, or inadequate response to another DMT.
- Rapidly evolving severe RRMS — as first-line in exceptionally active cases.
- NOT approved for primary progressive MS (PPMS) — only Ocrevus is.
What the pivotal trials showed
AFFIRM (RRMS)
A 2-year phase 3 trial of 942 patients comparing Tysabri with placebo ([Polman CH et al. NEJM 2006](https://www.nejm.org/doi/full/10.1056/NEJMoa044397)):
- 68% fewer relapses per year (ARR 0.23 vs 0.73).
- 92% fewer T1 Gd+ MRI lesions.
- 42% reduction in confirmed disability progression at 12 weeks.
- NEDA-3 in ~37% of patients at year 2.
SENTINEL (combination with interferon)
Showed additional efficacy but was halted in 2005 after two PML cases — leading to temporary withdrawal and later reintroduction under a strict REMS protocol ([Langer-Gould A et al. NEJM 2005](https://www.nejm.org/doi/full/10.1056/NEJMoa051847)).
TOP and real-world data
The Tysabri Observational Program (TOP) with over 6,000 patients and 10+ years of follow-up confirms durable efficacy: ~50% of patients remain relapse-free at year 5 ([Butzkueven H et al. JNNP 2020](https://jnnp.bmj.com/content/91/6/660)).
How it is given — infusion or subcutaneous
Tysabri is available in two formulations:
- IV infusion (300 mg every 4 weeks) — original formulation, ~1 hour infusion plus 1 hour of post-infusion observation early on.
- Subcutaneous injection (2 × 150 mg, 300 mg total) — approved in 2021 in the EU and US, takes ~15 minutes, administered at a day hospital by clinical staff ([EMA Tysabri SC update 2021](https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri); [Biogen press 2021](https://investors.biogen.com/news-releases/news-release-details/biogen-announces-eu-approval-tysabri-subcutaneous-injection)).
Extended Interval Dosing (EID)
The NOVA trial (2022) confirmed that dosing every 6 weeks instead of 4 maintains efficacy in stable patients and reduces PML risk by ~88% ([Foley JF et al. Lancet Neurol 2022](https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00143-0/fulltext)). EID is now standard for JCV-positive patients after the first year.
PML — the headline risk and how to monitor it
PML (progressive multifocal leukoencephalopathy) is a rare but serious viral brain infection caused by the JC virus, carried latently by ~50–60% of adults. Three risk factors ([Bloomgren G et al. NEJM 2012](https://www.nejm.org/doi/full/10.1056/NEJMoa1107829)):
1. JCV antibody status — JCV-negative patients have ~0.09/1000 risk.
2. Treatment duration — risk rises beyond year 2.
3. Prior immunosuppression — mitoxantrone, cyclophosphamide, azathioprine before Tysabri.
Risk stratification
JCV-negative: ~0.09/1000 (very low). JCV-positive, <2 years, no prior IS: ~0.7/1000. JCV-positive, 2–4 years, no prior IS: ~5.7/1000. JCV-positive, 2–4 years, with prior IS: ~13/1000 (high).
Monitoring
- JCV antibodies: before the first dose, then every 3–6 months.
- Brain MRI: every 6–12 months; in JCV-positive patients past 18 months consider every 3–4 months.
- JCV index: a higher index (>1.5) carries greater risk.
- Clinical picture: progressive personality change, cognitive decline, weakness that does not fit a typical relapse — get an urgent MRI.
Other safety considerations
Most common adverse events
- Infusion reactions (5–10%) — headache, nausea, mild flushing; usually mild.
- Upper respiratory and urinary tract infections.
- Fatigue and headache in the days after infusion.
Serious but rare risks
- PML (described above).
- Anaphylaxis: <1%, more common after the 2nd infusion — mandatory 1-hour observation during the first 12 infusions.
- Hepatotoxicity: rare; liver tests before each infusion.
- Anti-natalizumab antibodies: ~6% of patients develop antibodies that reduce efficacy and increase reactions.
"Rebound" on discontinuation
After stopping natalizumab, MS activity can return more aggressively than before therapy — 3–6 months after the last dose. Risk is highest in patients with highly active disease before Tysabri and JCV-positive patients switching to lower-efficacy DMTs. Strategies:
- No gap or only 4–8 weeks when switching to anti-CD20 (Ocrevus, Kesimpta) or Mavenclad.
- Avoid fingolimod, dimethyl fumarate, or glatiramer as the switch in active disease — too weak to prevent rebound.
Pregnancy and breastfeeding
Natalizumab is not teratogenic but crosses the placenta especially in the 3rd trimester and can transiently affect newborn blood counts (anaemia, thrombocytopenia). EAN 2022 guidance ([Dobson R et al. Eur J Neurol 2023](https://onlinelibrary.wiley.com/doi/10.1111/ene.15670)):
- Planned pregnancy: continue Tysabri until pregnancy is confirmed, then with the neurologist either stop or move to extended-interval dosing.
- Highly active disease: can continue EID (every 6 weeks) until weeks 30–34 to prevent rebound.
- After delivery: discuss restarting promptly (often within the first 6 weeks).
- Breastfeeding: usually delayed 12 hours after infusion; registry data show no harm to the infant.
Tysabri in Serbia — where it stands in 2026
Natalizumab (Tysabri) is on RFZO Lista C and 100% reimbursed by public insurance for patients with highly active relapsing-remitting MS who meet RFZO criteria ([RFZO Lista lekova](https://rfzo.rs/index.php/davalciusluga/lekovi-info/lekovi-lista)). It is prescribed through the MS-centre committee: KCS Belgrade, Niš Neurology Clinic, KC Vojvodine Novi Sad, KC Kragujevac, and the Military Medical Academy (VMA) Belgrade. The practical path:
1. The MS-centre neurologist evaluates disease activity (≥1 relapse in the prior year, MRI activity, EDSS).
2. Documentation goes to the RFZO committee — if criteria are met, therapy is approved.
3. Before the first infusion: JCV antibodies, CBC, liver tests, HBV/HIV, brain MRI, gynaecological/dermatological exam.
4. Infusions are given in the MS-centre day hospital every 4 weeks (or 6 weeks on EID).
5. Monitoring: JCV antibodies every 3–6 months; MRI every 6–12 months; CBC and liver before each infusion.
Tysabri compared with other DMTs
- vs Ocrevus / Kesimpta (anti-CD20): Tysabri acts faster (full effect by week 12) and has stronger ARR effects in very active disease. Anti-CD20 drugs have far lower PML risk and no rebound — so a common modern strategy is to use Tysabri as "induction" for 12–24 months, then switch to Ocrevus or Kesimpta.
- vs Mavenclad (cladribine): Tysabri requires continuous monthly dosing; Mavenclad is "induction and pause". Tysabri has lower sustained efficacy in ARR if stopped.
- vs fingolimod / siponimod (Gilenya / Mayzent): Tysabri is significantly stronger in active MS, but with higher PML risk in JCV-positive patients.
Practical tips for patients on Tysabri
- Vaccinations: complete before the first dose (HBV, pneumococcus, flu, COVID-19, zoster if 50+). No live vaccines while on therapy.
- JCV monitoring: track antibody status and index every 3–6 months.
- MRI: routine and immediately for any new symptoms — PML can mimic a relapse but has a different location and evolution.
- Symptom diary: record any new neurological symptom lasting >24 hours.
- Travel: infusions abroad can be arranged through Biogen's Tysabri Travel program; talk to your MS centre 4–6 weeks in advance.
- Discontinuation: never stop Tysabri on your own — always plan the switch with your neurologist to prevent rebound.
In 2026, Tysabri (natalizumab) remains one of the most effective therapies for highly active RRMS — with landmark AFFIRM data (68% fewer relapses, 92% fewer MRI lesions) and now a subcutaneous formulation for faster administration. Its main limitations are PML risk in JCV-positive patients and rebound on stopping — both manageable with strict monitoring and a planned switch. In Serbia it is 100% reimbursed via RFZO Lista C at MS centres. Tysabri remains a key option when rapid and powerful disease control is needed.
Sources
Polman CH et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis (AFFIRM). NEJM 2006: https://www.nejm.org/doi/full/10.1056/NEJMoa044397. Bloomgren G et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. NEJM 2012: https://www.nejm.org/doi/full/10.1056/NEJMoa1107829. Foley JF et al. Comparison of switching to 6-week dosing of natalizumab (NOVA). Lancet Neurol 2022: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00143-0/fulltext. Butzkueven H et al. Long-term safety and effectiveness of natalizumab (TOP). JNNP 2020. Dobson R et al. EAN consensus on pregnancy in MS. Eur J Neurol 2023. EMA EPAR — Tysabri: https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri. RFZO Lista lekova: https://rfzo.rs/index.php/davalciusluga/lekovi-info/lekovi-lista. This article is educational, does not constitute medical advice, and must not be used as the basis for changing therapy without consulting your MS-centre neurologist.